Vi inleder bevakning på mResell, en ledande svensk aktör inom re-commerce som specialiserar sig på r...
SRV’s Q2 figures fell short of our estimates for both volumes and profitability.
Redeye comments on q.beyond’s Q2 report showing a slightly more substantial improvement in EBITDA an...
Redeye returns with a more in-depth take on the Q2 report.
Administer reports Q2 on August 14. We expect net sales and profitability to remain broadly flat y/y...
Redeye negatively views Surgical Science’s profit warning for Q2 2025.
CapMan’s operative performance in Q2 on comparable basis was decent, although the operating profit f...
Suominen faced another setback on its earnings recovery path as US volumes were missing big time.
Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retino...
Redeye updates on G5 after weaker-than-expected Q2-results which have resulted in lowered estimates.
Redeye notes that BeammWave surprised by posting net sales of SEK1.
Suominen's Q2 report fell clearly short of Vara Research consensus expectations owing to very weak v...
CapMan's Q2 2025 results were largely in line with our expectations, with fee income declining sligh...
Rottneros reports SEK 140m impairment ahead of Q2 Challenging markets for Rottneros and Arctic Paper...
Suominen’s Q2 revenue dropped steeply as the tariff situation caused volatility in the US supply cha...
Suominen Q2 comparable EBITDA of EUR 3.2m came clearly below Vara Research consensus expectation of ...
Redeye provides an initial take following the release of Optomed’s Q2 2025 report.
DT’s Q2 revenue was slightly higher than expected, however the EUR 1.
CapMan’s Q2 results were decent, but the operating profit fell below expectations largely due to low...
